Why Juno Therapeutics Shares Are Going Up 21.2% Today
After the company released its third-quarter progress report and shared the latest data from its lead drug, JCAR017, shares of Juno Therapeutics (NASDAQ: JUNO) are shooting 21.2% higher at 2:30 p.m. EDT today.
There weren't any surprises in Juno Therapeutics' earnings release. Its collaboration revenue in the quarter was $44.8 million and, unsurprisingly, major research and development spending resulted in a loss of $0.73 per share.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
